The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery.

As pipelines across modalities diversify, regulatory scrutiny intensifies, and the margin for error in development execution continues to shrink, partnering with a CDMO has never been more critical.

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

Biopharma is embracing digital twins in a big way, with a growing number of companies using computational models to streamline and optimize more parts of the drug discovery, testing, and manufacturing ...

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on June 19 that it held the first AI Drug Discovery Advisory Committee of ...

DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract ...

IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world's largest pharma and biotech development teams, today ...

The U.S. Preclinical Imaging Market was valued at USD 1.12 Billion in 2025 and is projected to reach USD 1.85 Billion by 2035, while Europe is expected to grow from USD 1.28 Billion to USD 1.95 ...

Every major pharmaceutical company relies on real-world data to develop treatments, but most of that data comes from claims ...

This is read by an automated voice. Please report any issues or inconsistencies here. As a kid, I wanted to be an astronaut or a baseball player. When I realized I was prone to motion sickness, I ...

Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, ...